24/7 Wall St. on MSN10m
MicroStrategy Rebrands, but It Is the Same Risky InvestmentBecause of its cryptocurrency hoarding strategy, MicroStrategy (NASDAQ:MSTR) is now a big deal. It needs a new name to go along with its plus-sized game plan, so it has rebranded as Strategy. It is ...
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.
In Q3 FY2025, it reported $35.1 billion in revenue. up 94% year-over-year, with data center revenue up 112% to $30.8 billion. Non-GAAP EPS reached $0.81 and grew 103% year-over-year. These results ...
Amazon (AMZN) stock is pulling back, after a better-than-expected fourth quarter was overshadowed by a weak forecast ...
We recently compiled a list of the Why These 15 Bank Stocks Are Skyrocketing So Far In 2025. In this article, we are going to ...
We recently compiled a list of the Why These 15 Bank Stocks Are Skyrocketing So Far In 2025. In this article, we are going to ...
We recently compiled a list of the Why These 15 Bank Stocks Are Skyrocketing So Far In 2025. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback